Drug Search Results
More Filters [+]

Cenerimod

Alternative Names: cenerimod, act-334441, act334441, act 334441
Latest Update: 2024-12-10
Latest Update Note: Clinical Trial Update

Product Description

Cenerimod, a novel, potent and selective S1P1 receptor modulator with unique S1P1 receptor signaling properties and absence of broncho- and vasoconstrictor effects ex vivo and in vivo. Cenerimod dose-dependently lowered circulating lymphocyte counts in rats and mice after oral administration and effectively attenuated disease parameters in a mouse experimental autoimmune encephalitis (EAE) model. Cenerimod has potential as novel therapy with improved safety profile for autoimmune diseases with high unmet medical need.

Mechanisms of Action: S1P1 Modulator

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Idorsia
Company Location:
Company CEO:
Additonal Commercial Interests: Viatris Pharmaceuticals

Clinical Description

Map of Global Clinical Trials for Cenerimod

Countries in Clinic: Argentina, Brazil, Bulgaria, Chile, Czech Republic, France, Georgia, Germany, Greece, Hungary, Japan, Korea, Mexico, Peru, Philippines, Poland, Portugal, Puerto Rico, Romania, Serbia, South Africa, Spain, Taiwan, United States, Unknown Location

Active Clinical Trial Count: 13

Highest Development Phases

Phase 3: Lupus Erythematosus, Systemic

Phase 1: Healthy Volunteers|Kidney Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ID-064A303

P3

Unknown Status

Lupus Erythematosus, Systemic

2028-05-01

OPUS OLE

P3

Enrolling by invitation

Lupus Erythematosus, Systemic

2027-11-01

ID-064A302

P3

Unknown Status

Lupus Erythematosus, Systemic

2027-05-01

2024-515870-28-00

P3

Unknown Status

Lupus Erythematosus, Systemic

2027-05-01

Recent News Events